FIRST OUR TURNS OUT IN THE TREATMENT OF SEVERE OSTEOPOROSIS WITH TERIPARATIDE

Abstract

In Italy the osteoporosis cause approximately 250000 fracture/year. A useful aid in the treatment of this pathology comes from the Teriparatide, a synthetic form of the natural human parathyroid hormone, that stimulates the formation of new bone by increasing the number and action of bone-forming cells, unlike estrogen and bisphosphonate which are only able in slowing or stopping bone loss by blocking the action of osteoclasts. The Authors presents theirs first results after treatment with 20 mcg per day of Forsteo (Ely Lilly), trade name of the teriparatide, along with calcium (1000mg) and vitamin D (400UI) supplementation, for the previewed maximum period of 18 months, in women older than 65 years with unsatisfactory bisphosphonate treatment, T-score equal or inferior to −4, multiple vertebral osteoporotic fractures and one or more age-independent factors risk like: BMI< 19 kg/m2, maternal familiarity with neck-femoral fractures before 65 years old, premature menopause, conditions associated with the extended immobility. The treatment induced in all patients an increase of Ca plasmatic concentrations for 16–24 hours with a maximum peak in 4–6 hours. Condition like hypercalcemia, severe renal insufficiency, renal calculosis, hyperpara-thyroidism, Paget, alkaline hyperphosphatasaemia and previous therapy radiating are the main parameter of exclusion from the treatment.